Patents by Inventor David Harrich

David Harrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8828933
    Abstract: Disclosed are viral proteins associated with Human Immunodeficiency Virus (HIV) infections and mutants thereof, particularly, mutant Tat proteins capable of modulating multiple steps of the HIV-1 replication cycle. Also provided are methods of using the mutant Tat proteins, and pharmaceutical compositions comprising the same, for prevention and treatment of HIV-1 infections, and/or symptoms associated therewith.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: September 9, 2014
    Assignee: The Council of the Queensland Institute of Medical Research
    Inventor: David Harrich
  • Publication number: 20120115775
    Abstract: Disclosed are viral proteins associated with Human Immunodeficiency Virus (HIV) infections and mutants thereof, particularly, mutant Tat proteins capable of modulating multiple steps of the HIV-1 replication cycle. Also provided are methods of using the mutant Tat proteins, and pharmaceutical compositions comprising the same, for prevention and treatment of HIV-1 infections, and/or symptoms associated therewith.
    Type: Application
    Filed: November 9, 2011
    Publication date: May 10, 2012
    Applicant: The Council of the Queensland Institute of Medical Research
    Inventor: David Harrich
  • Patent number: 5994108
    Abstract: Transdominant HIV tat substitution and truncated gene mutants of 72 amino acid residues or less are disclosed. The mutated genes encode mutant Tat proteins which are capable of inhibiting the expression of the HIV-1 virus in the presence of an equimolar concentration of the wild type Tat protein in vitro. Therapeutic agents which include fused protein forms of the mutant proteins are also disclosed, as well as methods of preparing and using the therapeutic agents in the treatment of HIV infection and HIV-related injections in an animal. Recombinant vectors which express the mutant HIV Tat proteins described are also disclosed, as well as cell lines which product high yields of the mutant HIV. Also provided are cell lines that express enhanced levels of TAR mutant viruses relative to other TAR mutant infected cell lines. Levels of production are enhanced by the use of cell lines that express a transactivator protein, such as adenovirus transactivator EIA and/or EIB protein.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: November 30, 1999
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard B. Gaynor, David Harrich
  • Patent number: 5686264
    Abstract: Transdominant HIV tat substitution and truncated gene mutants of 72 amino acid residues or less are disclosed. The mutated genes encode mutant Tat proteins which are capable of inhibiting the expression of the HIV-1 virus in the presence of an equimolar concentration of the wild type Tat protein in vitro. Therapeutic agents which include fused protein forms of the mutant proteins are also disclosed, as well as methods of preparing and using the therapeutic agents in the treatment of HIV infection and HIV-related injections in an animal. Recombinant vectors which express the mutant HIV Tat proteins described are also disclosed, as well as cell lines which product high yields of the mutant HIV.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: November 11, 1997
    Assignee: Board of Regents, The University of Texas Sys
    Inventors: Richard B. Gaynor, Joseph A. Garcia, David Harrich
  • Patent number: 5597895
    Abstract: Transdominant HIV tat substitution and truncated gene mutants of 72 amino acid residues or less are disclosed. The mutated genes encode mutant Tat proteins which are capable of inhibiting the expression of the HIV-1 virus in the presence of an equimolar concentration of the wild type Tat protein in vitro. Therapeutic agents which include fused protein forms of the mutant proteins are also disclosed, as well as methods of preparing and using the therapeutic agents in the treatment of HIV infection and HIV-related injections in an animal. Recombinant vectors which express the mutant HIV Tat proteins described are also disclosed, as well as cell lines which product high yields of the mutant HIV.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: January 28, 1997
    Assignee: Board of Regents, University of Texas System
    Inventors: Richard B. Gaynor, Joseph A. Garcia, David Harrich